Overexpression of oncogenes (FLT3, MYB, DNMT3B, and MYCN) in DX vs CR1 samples reinforces their usefulness in minimal residual disease monitoring, especially in AML-NK with no genetic aberrations. This evidence concerns the gene DNMT3B and acute myeloid leukemia.